The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2010Mechanism and Modulation of Alpha-Synuclein Expression
Promising Outcomes of Original Grant:
In the initial grant, we tested the hypothesis that GATA-2 is a direct regulator of alpha-synuclein expression in dopaminergic neurons and therefore represents a... -
Rapid Response Innovation Awards, 2010In Vivo Assessment of Alpha-Synuclein Secretion
Objective/Rationale:
Recent data from our lab (Emmanouilidou et al, 2010) suggest that cell-produced physiologically secreted alpha-synuclein can cause the death of neuronal recipient cells. Although... -
MJFF Research Grant, 2010Regulated rAAV-GDNF to treat Parkinson's disease: Translational research plan
Objective/Rationale:
We are attempting to perfect gene therapy using glial cell line-derived neurotrophic factor (GDNF) for Parkinson’s disease. One part of developing this gene therapy is... -
Neurotrophic Factor Therapies for Parkinson's Disease, 2010CDNF (Cerebral Dopamine Neurotrophic Factor) for Therapy of Parkinson's Disease
Objective/Rationale:
CDNF protein is expressed in human brain, acts differently from known neurotrophic factors and can protect and repair dopamine neurons in two pre-clinical models of Parkinson’s... -
Rapid Response Innovation Awards, 2010Selective Neuroprotective Effects of the S18Y Polymorphic Variant of UCH-L1
Promising Outcomes of Original Grant:
We were able to replicate in an in vivo setting in the nigrostriatal system our previous observation in neuronal cell cultures that lack of UCH-L1 did not alter... -
Rapid Response Innovation Awards, 2010Dopamine D1-D3 Receptor Heteromer as a New Target for Parkinson's Disease
Objective/Rationale:
Receptor heteromers must be understood as dimeric or higher order molecular entities that are the result of combinatorial evolution and that are endowed with unique...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.